TRBN vs. OSIR

OSIR:

1. Osiris Therapeutics (OSIR17.02, +2.00, +13.3%) priced 3.5 million shares at $11, the low end of its $11-$13 price range, in a bid to raise $39 million in its IPO. OSIR is now rising up now 17.8 A/H of Friday.

TRBN:

1. The company plans to use net proceeds from the offering and a private placement with Wyeth (WYE.N: Quote, Profile, Research) for general corporate purposes, including clinical trials, research and development, manufacturing, and possible acquisitions. Wyeth has agreed to purchase 800,000 shares of common stock at the IPO price in a private placement concurrent with the public offering, according to a document filed with the U.S. Securities and Exchange Commission. In January, Wyeth also reach an agreement with the Seattle-based company to develop and co-market Trubion's treatments for inflammatory diseases and cancer. Underwriters, led by Morgan Stanley, will have the option to buy another 600,000 shares to cover overallotments.
2. The stock opened at $13, which was the 4-million-share offering price and the low end of the expected range. The biotech company focuses on autoimmune disease and cancer. Trubion has entered into a collaboration agreement with Wyeth over its lead rheumatoid arthritis product, which began a Phase IIb trial in September.
3. TRU-015 for the Treatment of Rheumatoid Arthritis. According to Datamonitor, rheumatoid arthritis, or RA, is estimated to affect approximately 4.3 million people in the United States, Japan and Europe. Total reported worldwide sales of protein therapeutics used for the treatment of RA were $7.6 billion in 2005 and are expected to grow to $10 billion in 2010.